Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Protagonist Therapeutics, Inc. - Common Stock (NQ:PTGX)

56.37 +0.05 (+0.09%)
Streaming Delayed Price Updated: 4:00 PM EDT, Jun 13, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 985,411
Open 55.54
Bid (Size) 56.39 (1)
Ask (Size) 56.40 (8)
Prev. Close 56.32
Today's Range 55.54 - 57.18
52wk Range 30.67 - 60.60
Shares Outstanding 61,928,760
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
9 Analysts Assess Protagonist Therapeutics: What You Need To Know
Via Benzinga
Protagonist and Takeda Announce ASCO Plenary Presentation Highlighting Full 32-Week Results from Phase 3 VERIFY Study of Rusfertide, Showing Reductions in Phlebotomy, Improved Hematocrit Control in Polycythemia Vera
From Takeda Pharmaceutical Company Limited
Via Business Wire

Performance

YTD
+44.6%
+44.6%
1 Month
+27.3%
+27.3%
3 Month
+2.7%
+2.7%
6 Month
+39.6%
+39.6%
1 Year
+65.9%
+65.9%

More News

Read More
Protagonist Therapeutics to Participate in the Jefferies Global Healthcare Conference 2025
Via ACCESS Newswire
PROTAGONIST THERAPEUTICS INC (NASDAQ:PTGX) showing some interesting technicals. Here's why.
Via Chartmill
Protagonist/Johnson & Johnson Partnered Drug Shows Significant Skin Clearance In Pivotal Psoriasis Study
Via Benzinga
Protagonist Announces Icotrokinra Phase 3 Data on Difficult-to-Treat Scalp and Genital Psoriasis and Preclinical Data on PN-881 Presented at the Society for Investigative Dermatology Annual Meeting
Via ACCESS Newswire
Protagonist Reports First Quarter 2025 Financial Results and Provides Corporate Update
Via ACCESS Newswire
Protagonist Therapeutics Announces Plenary Presentation on VERIFY Phase 3 Study with Rusfertide at ASCO 2025
Via ACCESS Newswire
Protagonist Therapeutics Reports Granting of Inducement Award
Via ACCESS Newswire
Johnson & Johnson, Protagonist Tout Positive Results For Psoriasis Oral Pill Study
Via Benzinga
Icotrokinra Results Show 75% of Adolescents with Plaque Psoriasis Achieved Completely Clear Skin and Demonstrate Favorable Safety Profile with a Once Daily Pill
Via ACCESS Newswire
Does PROTAGONIST THERAPEUTICS INC (NASDAQ:PTGX) align with Mark Minervini’s trading strategy?
Via Chartmill
Protagonist Therapeutics Named to Fast Company's Annual List of the World's Most Innovative Companies of 2025
Via ACCESS Newswire
D-Wave Quantum And IonQ Are Among Top Mid-Cap Stock Gainers Last Week (Mar 10-Mar 14): Are The Others In Your Portfolio?
Via Benzinga
Gilead Sciences To Rally Around 11%? Here Are 10 Top Analyst Forecasts For Tuesday
Via Benzinga
Keep an eye on the top gainers and losers in Monday's session.
Via Chartmill
Monday's session: top gainers and losers
Via Chartmill
Let's uncover which stocks are experiencing notable gaps during today's session.
Via Chartmill
Redfin, Mineralys Therapeutics, Trevi Therapeutics And Other Big Stocks Moving Higher On Monday
Via Benzinga
Top movers in Monday's pre-market session
Via Chartmill
Why Is Protagonist Therapeutics Stock Trading Higher On Monday?
Via Benzinga
Protagonist Therapeutics Unveils 'Paradigm-Shifting' Drug And Breaks Out
Via Investor's Business Daily
Protagonist Reports Positive Top Line Results From Phase 2b Study of Icotrokinra Showing Potential to Transform the Treatment Paradigm for Patients With Ulcerative Colitis
Via ACCESS Newswire
Icotrokinra Clinical Study Results Demonstrate Its Potential to Shift Treatment Paradigm and Set a New Standard for Treatment in Plaque Psoriasis
Via ACCESS Newswire
Takeda-Protagonist Therapeutics Partnered Investigational Drug Hits Primary Goal In Late-Stage Study In Patients With Type Of Blood Cancer
Via Benzinga

Frequently Asked Questions

Is Protagonist Therapeutics, Inc. - Common Stock publicly traded?
Yes, Protagonist Therapeutics, Inc. - Common Stock is publicly traded.
What exchange does Protagonist Therapeutics, Inc. - Common Stock trade on?
Protagonist Therapeutics, Inc. - Common Stock trades on the Nasdaq Stock Market
What is the ticker symbol for Protagonist Therapeutics, Inc. - Common Stock?
The ticker symbol for Protagonist Therapeutics, Inc. - Common Stock is PTGX on the Nasdaq Stock Market
What is the current price of Protagonist Therapeutics, Inc. - Common Stock?
The current price of Protagonist Therapeutics, Inc. - Common Stock is 56.37
When was Protagonist Therapeutics, Inc. - Common Stock last traded?
The last trade of Protagonist Therapeutics, Inc. - Common Stock was at 06/13/25 04:00 PM ET
What is the market capitalization of Protagonist Therapeutics, Inc. - Common Stock?
The market capitalization of Protagonist Therapeutics, Inc. - Common Stock is 3.49B
How many shares of Protagonist Therapeutics, Inc. - Common Stock are outstanding?
Protagonist Therapeutics, Inc. - Common Stock has 3B shares outstanding.
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.